Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NEOGENOMICS INC : Other Events (form 8-K)

06/08/2021 | 05:09pm EDT

Item 8.01 Other Events.

NeoGenomics, Inc. (the "Company") has appointed Broadridge Corporate Issuer Solutions, Inc. ("Broadridge") as its transfer agent, effective June 4, 2021. All of the Company's shareholder records were transferred from Standard Registrar and Transfer Company to Broadridge.

Broadridge may be contacted via telephone at (888) 789-8606 or (303) 562-9275 or at the following addresses:



Regular Mail                                         Overnight Mail

Broadridge Shareholder Services                      Broadridge Shareholder Services
c/o Broadridge Corporate Issuer Solutions            c/o Broadridge Corporate Issuer Solutions
PO Box 1342                                          1155 Long Island Avenue
Brentwood, NY 11717-0718                             Edgewood, NY 11717-8309
                                                     Attn: IWS

© Edgar Online, source Glimpses

All news about NEOGENOMICS, INC.
09/09NEOGENOMICS' : Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Fur..
PU
09/01NEOGENOMICS : to Participate in the Morgan Stanley 19th Annual Global Healthcare Conferenc..
PU
08/26NEOGENOMICS : Benchmark Capital Adjusts NeoGenomics' Price Target to $50 From $46, Maintai..
MT
08/13INSIDER TRENDS : NeoGenomics Insider Sells for Tax Adds to 90-Day Selling Trend
MT
08/10NEOGENOMICS INC : Regulation FD Disclosure (form 8-K)
AQ
08/09NEOGENOMICS : Morgan Stanley Adjusts Price Target on NeoGenomics to $58 From $64, Maintain..
MT
08/06NEOGENOMICS : Q2 Earnings Snapshot
AQ
08/06NEOGENOMICS : Q2 Net Loss Narrows, Revenue Rises, Reiterates Guidance; Shares Edge Higher ..
MT
08/06NeoGenomics Seeks M&A
CI
08/06NEOGENOMICS INC : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 500 M - -
Net income 2021 16,8 M - -
Net Debt 2021 157 M - -
P/E ratio 2021 391x
Yield 2021 -
Capitalization 5 772 M 5 772 M -
EV / Sales 2021 11,9x
EV / Sales 2022 10,2x
Nbr of Employees 1 700
Free-Float 96,0%
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 46,94 $
Average target price 56,80 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Douglas M. Van Oort Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors